• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Immunotherapy in Oncology Drug Pipeline Update 2015

  • ID: 1196685
  • January 2015
  • Region: Global
  • Bioseeker

Cancer immunotherapy offers an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. In this Drug Pipeline Update the author brings together the fields of antibodies, vaccines, and immunostimulators in oncology drug development into one source.

There are today 641 companies plus partners developing 1064 cancer immunotherapy drugs in 2994 developmental projects in cancer. In addition, there are 19 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 563 drugs. Immunotherapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 481 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 430 out of the 436 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 71 classifications READ MORE >

Note: Product cover images may vary from those shown

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)